December 13, 2018 10:59 AM EST
News Briefing

Lil­ly, In­cyte's baric­i­tinib wins fast-track sta­tus for hard-to-treat lu­pus; Syn­thorx ham­mers out $150M+ IPO

ENDPOINTS

→ Rheuma­toid arthri­tis drug Olu­mi­ant — ap­proved for a nar­row­er-than-ex­pect­ed pa­tient pop­u­la­tion ear­li­er this year to the dis­may of its man­u­fac­tur­er Eli Lil­ly $LLY and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times